Galapagos GLPG2737-CL-202

The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be [2]

Study Name on ClinicalTrials.gov (link is external) [3]	GLPG2737 on top of Orkambi in subjects with cystic fibrosis
Study Drug	GLPG2737
Type of Study Drug	CFTR modulator
Study Title	A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation
Study Phase	2a
Study Sponsor	Galapagos
Link on clinicaltrials.gov (link is external) [3]	https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002181-42/DE [4]
Participating ECFS-CTN sites	Please contact ecfs-ctn@uzleuven.be [5] for most recent sitelist
Age	18 years and older

Back to Studies Overview [1]